How much is BeiGene stock worth?

Biotechnology company Amgen announced Thursday it is investing $2.7 billion in BeiGene, taking a 20.5% stake in the Chinese biotech firm. The all-cash deal values BeiGene at $174.85 per American depository share, a 25% premium to BeiGene’s closing price on the Nasdaq on Wednesday. BeiGene’s stock jumped 7% in after-hours trading Thursday.

What is the volume of BeiGene Ltd (bgne) stock?

Having a second look at BeiGene Ltd. (NASDAQ:BGNE) provides that stock’s average daily trading volume for 3 months was 239.22K, while it jumped to 0.21 million when we calculate an average volume for past 10 days. Number of outstanding shares of the stock stood at 102.81 million.

How much did BeiGene IPO cost?

BeiGene (BGNE) raised $126 million in an initial public offering (IPO) on Wednesday, February 3rd 2016. The company issued 5,500,000 shares at a price of $22.00-$24.00 per share. Goldman Sachs, Morgan Stanley and Cowen and Company served as the underwriters for the IPO and Baird was co-manager. Who are BeiGene's major shareholders?